{"drugs":["M-M-R II","Measles, Mumps, Rubella Vaccine, Live"],"mono":{"0":{"id":"363130-s-0","title":"Generic Names","mono":"Measles, Mumps, Rubella Vaccine, Live"},"1":{"id":"363130-s-1","title":"Dosing and Indications","sub":{"0":{"id":"363130-s-1-4","title":"Adult Dosing","mono":"<b>Measles-mumps-rubella vaccination:<\/b> 0.5 mL SUBQ "},"1":{"id":"363130-s-1-5","title":"Pediatric Dosing","mono":"<b>Measles-mumps-rubella vaccination:<\/b> 0.5 mL SUBQ, first dose at 12 to 15 months and second dose at 4 to 6 years; do not delay first dose past 15 months of age because of increased risk of postvaccination seizures; may give second dose before age 4 years as long as at least 28 days have elapsed since the first dose."},"3":{"id":"363130-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Measles-mumps-rubella vaccination<br\/>"}}},"3":{"id":"363130-s-3","title":"Contraindications\/Warnings","sub":[{"id":"363130-s-3-9","title":"Contraindications","mono":"<ul><li>active febrile infection or febrile respiratory illness (manufacturer); acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction (CDC)<\/li><li>anaphylactic or anaphylactoid reactions to neomycin; reconstituted vaccine contains approximately 25 mcg\/dose; history of contact dermatitis, delayed-type cell-mediated immune response to neomycin is not a contraindication<\/li><li>bone marrow or lymphatic disorders, including blood dyscrasias, leukemia, lymphomas of any type, and other malignant neoplasms affecting the bone marrow or lymphatic systems<\/li><li>concomitant immunosuppressive therapy, except corticosteroids as replacement therapy (eg, Addison's disease)<\/li><li>congenital or hereditary immunodeficiency, family history, until immunocompetence of potential vaccine recipient is verified<\/li><li>hypersensitivity to any component of the vaccine, including gelatin<\/li><li>HIV with severe immunocompromise (age-specific CD4+ T-lymphocyte less than 15%) (CDC)  including AIDS- and HIV-associated infections (manufacturer)<\/li><li>immunodeficiency, severe (eg, from hematologic and solid tumors, congenital immunodeficiency, long-term immunosuppressive therapy (prednisolone 20 mg or 2 mg\/kg daily or equivalent corticosteroid for 2 weeks or longer)), primary or acquired immunodeficiency, cellular immune deficiencies, and hypogammaglobulinemic\/dysgammaglobulinemic states; measles inclusion body encephalitis, pneumonitis, and death have been reported in immunocompromised persons inadvertently vaccinated with measles-containing vaccine (manufacturer)<\/li><li>pregnancy; avoid pregnancy for 3 months following vaccination<\/li><\/ul>"},{"id":"363130-s-3-10","title":"Precautions","mono":"<ul><li>antibody-containing products; blood or plasma transfusions or immune globulin administration within previous 11 months (specific interval depends on product)<\/li><li>cerebral injury, history, or any condition where stress due to temperature elevation should be avoided<\/li><li>concomitant chemotherapy or radiation therapy; live vaccine should not be administered for at least 3 months unless benefit outweighs risk of adverse reactions<\/li><li>convulsions, individual or family history or any condition where stress due to temperature elevation should be avoided<\/li><li>HIV-infected patients without immunocompromise; immunization may be less effective<\/li><li>hypersensitivity (anaphylactic, anaphylactoid, or immediate reaction after ingestion) to eggs; vaccine contains trace chick embryo antigen; evaluate risk-to-benefit ratio; does not include allergies to chickens or chicken feathers<\/li><li>TB, untreated, active or suspected; do not vaccinate until after treatment<\/li><li>TB skin test; temporary depression of test sensitivity; administer test before or simultaneously with MMR vaccine  or unless urgent postpone test until at least 4 weeks after MMR vaccination<\/li><li>thrombocytopenia, current or history  or history of thrombocytopenic purpura; potential exacerbation or development with repeated doses; evaluate risk-to-benefit ratio<\/li><li>women of childbearing age; avoid pregnancy for 3 months following vaccination<\/li><li>report suspected adverse events to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967<\/li><\/ul>"},{"id":"363130-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Measles Virus Vaccine, Live: C (FDA)<\/li><li>Mumps Virus Vaccine, Live: C (FDA)<\/li><li>Mumps Virus Vaccine, Live: B2 (AUS)<\/li><li>Rubella Virus Vaccine, Live: C (FDA)<\/li><li>Rubella Virus Vaccine, Live: B2 (AUS)<\/li><\/ul>"},{"id":"363130-s-3-12","title":"Breast Feeding","mono":"<ul><li>Measles Virus Vaccine, Live: WHO: Compatible with breastfeeding.<\/li><li>Measles Virus Vaccine, Live: Micromedex: Infant risk is minimal.<\/li><li>Mumps Virus Vaccine, Live: WHO: Compatible with breastfeeding.<\/li><li>Mumps Virus Vaccine, Live: Micromedex: Infant risk is minimal.<\/li><li>Rubella Virus Vaccine, Live: WHO: Compatible with breast-feeding.<\/li><li>Rubella Virus Vaccine, Live: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"363130-s-4","title":"Drug Interactions","sub":{"1":{"id":"363130-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Alemtuzumab (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Meningococcal Vaccine (probable)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Teriflunomide (theoretical)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"363130-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Cytomegalovirus Immune Globulin, Human (probable)<\/li><li>Hepatitis B Immune Globulin (probable)<\/li><li>Leflunomide (established)<\/li><li>Rabies Immune Globulin (probable)<\/li><li>Respiratory Syncytial Virus Immune Globulin, Human (probable)<\/li><li>Tetanus Immune Globulin (probable)<\/li><li>Vaccinia Immune Globulin, Human (probable)<\/li><li>Varicella-Zoster Immune Globulin (probable)<\/li><\/ul>"}}},"5":{"id":"363130-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Arthritis<\/li><li><b>Other:<\/b>Fever<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Hematologic:<\/b>Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Afebrile seizure, Encephalitis, Encephalopathy, Febrile seizure, Guillain-Barr  syndrome, Measles inclusion body encephalitis<\/li><li><b>Ophthalmic:<\/b>Optic neuritis, Retrobulbar neuritis<\/li><li><b>Respiratory:<\/b>Pneumonitis<\/li><\/ul>"},"6":{"id":"363130-s-6","title":"Drug Name Info","sub":[{"id":"363130-s-6-17","title":"US Trade Names","mono":"M-M-R II<br\/>"},{"id":"363130-s-6-18","title":"Synonyms","mono":"<ul><li>MMR Vaccine - Measles, Mumps, and Rubella Virus Vaccine, Live<\/li><li>Measles, Mumps, and Rubella Virus Vaccine, Live<\/li><\/ul>"},{"id":"363130-s-6-19","title":"Class","mono":"Vaccine<br\/>"},{"id":"363130-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}]},"7":{"id":"363130-s-7","title":"Mechanism Of Action","mono":"Measles, mumps and rubella vaccine is a live virus vaccine preparation for simultaneous vaccination against measles (rubeola), mumps and rubella (German measles) diseases. It is highly immunogenic and stimulates measles hemagglutination-inhibition (HI) antibodies, mumps neutralizing antibodies and rubella HI antibodies in susceptible individuals.<br\/>"},"9":{"id":"363130-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for SUBQ use only; do not administer IV or IM<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>do not give concurrently with immune globulin<\/li><li>give preferably into outer aspect of upper arm<\/li><li>reconstitute with supplied diluent; shake well<\/li><li>use within 8 hours of reconstitution<\/li><li>should be given 1 month before or after administration of other live viral vaccines<\/li><\/ul><\/li><\/ul>"},"13":{"id":"363130-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel female patients of childbearing age to use reliable contraception to avoid pregnancy for at least 3 months post-vaccination.<\/li><li>This vaccination should be deferred at least 3 months following blood or plasma transfusions and administration of immune globulin.<\/li><li>This drug may cause arthralgia or arthritis in female patients. Drug may also cause lymphadenopathy, myalgia, or symptoms of the common cold.<\/li><li>Advise patient to report fever or signs\/symptoms of thrombocytopenia or Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering).<\/li><li>Patient should also report signs\/symptoms of optic neuritis, polyneuritis, or polyneuropathy.<\/li><li>Tell patient to avoid other vaccines one month before or one month after having this vaccine, unless approved by healthcare professional.<\/li><li>Advise pediatric patients to call healthcare professional if a vaccination is missed, as drug should be given in a fixed series.<\/li><\/ul>"}}}